Pediatric Neurology News

Expanding newborn screening to identify genes associated with an increased risk for neurodevelopmental disorders could exacerbate disparities, among other drawbacks, experts wrote in Pediatrics.

PHILADELPHIA — Adolescents who sustained a concussion registered altered reaction time and decision-making when asked to execute basic maneuvers during a distracted driving simulation compared to those without, according to a presenter.

Compared with absolute values, serum neurofilament light chain Z scores were linked to higher effect size metrics and more accurate estimation of persistent neuroaxonal damage in pediatric populations, per data from The Lancet Neurology.

Stoke Therapeutics Inc. has announced new positive data regarding its proprietary antisense oligonucleotide therapeutic to treat Dravet syndrome.

The first patient has been dosed in a clinical trial with electron accelerator-produced Cu-67, according to a Wisconsin-based company specializing in radiopharmaceuticals for therapeutic and medical imaging applications announced.

Young brain donors exposed to repetitive head impacts through contact sports displayed cognitive and neurobehavioral symptoms with or without a diagnosis of chronic traumatic encephalopathy, according to research from JAMA Neurology.

Possible biomarkers of an adolescent’s risk for developing mental health issues include alterations in proteins involved with immune responses, blood coagulation and other pathways, data show.

Peer victimization and suicidality were associated with higher headache frequency in adolescents, while the association between headache and gender diversity weakened after controlling for other factors, according to research in Neurology.

A Virginia-based biotech company has announced dosing of the first patient in a phase 2 clinical trial examining safety and efficacy of its investigational anti-inflammatory peptide, RLS-0071, to treat hypoxic ischemic encephalopathy in newborns.

A biotechnology company has announced positive safety and efficacy data from two ongoing phase 1/2a studies as well as an open-label extension study of STK-001 to treat younger individuals with Dravet syndrome.